A combination of lymphatic drug delivery of anti‐ CTLA ‐4 antibody and local radiotherapy for solid‐tumor treatment
Cancer Science · 2024
DOI: 10.1111/cas.16369 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Koki Takagi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Radioimmunotherapy, Drug Delivery Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Suzuken Memorial Foundation.
Abstract (Originalsprache)
The combination of radiotherapy and immunotherapy is a promising approach that has been shown in clinical trials to improve significantly survival and response rates compared with monotherapy against solid tumor. Since anti‐CTLA‐4 antibodies block immunosuppressive signals mainly in the lymph nodes (LNs), efficient drug delivery to the lymphatic system is desirable. However, the immune checkpoint inhibitors, especially anti‐CTLA‐4 are currently administered intravenously (i.v.), resulting in limited efficacy in controlling solid tumor and inhibiting metastases, and the method of administration has not been optimized. Here, we show that a combination of local radiotherapy and administration of anti‐CTLA‐4 antibodies using a lymphatic drug delivery system (LDDS) suppresses solid tumor and metastases. We compared the efficacy of LDDS‐based immunotherapy or radioimmunotherapy with i.v. administration in a solid‐tumor model created by subcutaneous inoculation into LN‐swollen mice with osteosarcoma cells. Tumor‐bearing mice were divided into various groups (no treatment, immunotherapy [i.v. or LDDS], radiotherapy, and radioimmunotherapy [i.v. or LDDS]) and were observed for 28 days. Immunotherapy was administered with a cumulative dose of 10 mg/kg of anti‐CTLA‐4 monoclonal antibody, and radiotherapy was administered with a cumulative 8 Gy of fractionated X‐ray irradiation. For immunotherapy alone, LDDS provided slight tumor growth inhibition but did not inhibit distant metastasis. For radioimmunotherapy, however, tumor growth was delayed and distant metastasis was suppressed compared with radiotherapy alone. In particular, the LDDS group achieved a high tumor‐suppressive effect with T cell‐mediated immune activity, indicating the efficacy of LDDS in radioimmunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Miyagi, Japan.
- Division of Oral and Maxillofacial Oncology and Surgical Sciences, Graduate School of Dentistry, Tohoku University, Sendai, Miyagi, Japan.
- Biomedical Engineering Cancer Research Center, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Miyagi, Japan.
- Department of Radiological Technology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
- Department of Radiation Disaster Medicine, International Research Institute of Disaster Science, Tohoku University, Sendai, Miyagi, Japan.
ORCID-Profile: Ariunbuyan Sukhbaatar, Tetsuya Kodama
Förderung
- Japan Society for the Promotion of Science
- Suzuken Memorial Foundation
Zitieren
APA
Takagi, K., Sukhbaatar, A., Inaba, Y., Mori, S., & Kodama, T. (2024). A combination of lymphatic drug delivery of anti‐ CTLA ‐4 antibody and local radiotherapy for solid‐tumor treatment. Cancer Science. https://doi.org/10.1111/cas.16369
Vancouver
Takagi K, Sukhbaatar A, Inaba Y, Mori S, Kodama T. A combination of lymphatic drug delivery of anti‐ CTLA ‐4 antibody and local radiotherapy for solid‐tumor treatment. Cancer Science. 2024. doi:10.1111/cas.16369
BibTeX
@article{Takagi2024,
author = {Takagi, Koki and Sukhbaatar, Ariunbuyan and Inaba, Yohei and Mori, Shiro and Kodama, Tetsuya},
title = {A combination of lymphatic drug delivery of anti‐ CTLA ‐4 antibody and local radiotherapy for solid‐tumor treatment},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16369}
}
EUVIMED